eResearchTechnology, Inc. Announces Stock Buy-back Program Increase to 12.5 Million Shares

eResearchTechnology, Inc. Announces Stock Buy-back Program
Increase to 12.5 Million Shares 


PHILADELPHIA, May 3  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(NASDAQ:ERES) ("eRT" or "the company"), a leading provider of technology and
services to the pharmaceutical, biotechnology and medical device industries,
announced today that its Board of Directors authorized the purchase of up to an
additional 10 million shares, which extends the previously announced stock
buy-back program to authorize the repurchase of a total of 12.5 million shares.

The buy-back authorization allows the company to make purchases from time to
time on the open market at prevailing prices or in privately negotiated
transactions.  eRT's management will make the purchase decisions based upon
market conditions and other considerations.  As of the current date, the
company has purchased 2,005,000 shares under this program and is now authorized
to purchase up to an additional 10,495,000 shares.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  As a result, actual results may differ materially from any financial
outlooks stated herein.  Further information on potential factors that could
affect the company's financial results can be found in the company's Report on
Form 10-K filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Bruce Johnson of eResearchTechnology, [phone], or Matt

Hayden of Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/

Copyright